Skip to main content

BCAL Diagnostics Limited (BDX.AX)

Australian Securities Exchange Healthcare Medical - Diagnostics & ResearchView data quality →
27.3Poor

ValueMarkers Composite Index

Top 0%#44,696 of 44,714

DCF data not available

Piotroski
2/9
Weak
Beneish
-9.73
Low Risk
Altman
-1.27
Distress
DCF Value
-
Overvalued
ROIC
-106.6%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

BCAL Diagnostics Limited (BDX.AX) — VMCI valuation read

Composite valuation read on BDX.AX: VMCI 27/100 against a Healthcare sector median of 50. The 23-point below-median print is the headline number for BCAL Diagnostics Limited, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for BDX.AX: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on BDX.AX: BDX.AX trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of 0.6x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

BDX.AX rose 2.3% over the trailing 7 days, with a -0.9% read on a 30-day basis.

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

CEO: Shane RyanAUwww.bcaldiagnostics.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BDX.AX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.